Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Choosebetweenamab for Severe Asthma
NCT04585997Phase 4Unknown
- Sponsor
- University of Newcastle
- Start
- Nov 2018
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of mepolizumab, omalizumab in eosinophilic asthma (EA), sponsored by University of Newcastle. Status: unknown.
02
Drugs
mepolizumabomalizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT04585997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04585997.